Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 286

1.

Cathelicidin LL37 Promotes Epithelial and Smooth-Muscle-Like Differentiation of Adipose-Derived Stem Cells through the Wnt/β-Catenin and NF-κB Pathways.

Li Y, Shan Z, Yang B, Yang D, Men C, Cui Y, Wu J.

Biochemistry (Mosc). 2017 Nov;82(11):1336-1345. doi: 10.1134/S0006297917110116.

PMID:
29223160
2.

Is cathelicidin a novel marker of diabetic microangiopathy in patients with type 1 diabetes?

Uruska A, Michalska A, Ostrowska J, Skonieczna P, Lipski D, Uruski P, Pakuła M, Tykarski A, Zozulinska-Ziolkiewicz D.

Clin Biochem. 2017 Dec;50(18):1110-1114. doi: 10.1016/j.clinbiochem.2017.09.023. Epub 2017 Sep 28.

PMID:
28964758
3.

Serum level of cathelicidin LL-37 in patients with active tuberculosis and other infectious diseases.

Majewski K, Agier J, Kozłowska E, Brzezińska-Błaszczyk E.

J Biol Regul Homeost Agents. 2017 Jul-Sep;31(3):731-736.

PMID:
28956425
4.

Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease.

Kusaka S, Nishida A, Takahashi K, Bamba S, Yasui H, Kawahara M, Inatomi O, Sugimoto M, Andoh A.

Clin Exp Immunol. 2018 Jan;191(1):96-106. doi: 10.1111/cei.13047. Epub 2017 Sep 28.

PMID:
28872665
5.

Carbon Nanoparticles Inhibit the Antimicrobial Activities of the Human Cathelicidin LL-37 through Structural Alteration.

Findlay F, Pohl J, Svoboda P, Shakamuri P, McLean K, Inglis NF, Proudfoot L, Barlow PG.

J Immunol. 2017 Oct 1;199(7):2483-2490. doi: 10.4049/jimmunol.1700706. Epub 2017 Aug 16.

6.

A Preclinical Study of Cell-seeded Tubularized Scaffolds Specially Secreting LL37 for Reconstruction of Long Urethral Defects.

Li Y, Wu J, Feng F, Men C, Yang D, Gao Z, Zhu Z, Cui Y, Zhao H.

Anticancer Res. 2017 Aug;37(8):4295-4301.

PMID:
28739721
7.

Serum levels of peptide cathelicidin LL-37 in elderly patients with depression.

Kozłowska E, Wysokiński A, Brzezińska-Błaszczyk E.

Psychiatry Res. 2017 Sep;255:156-160. doi: 10.1016/j.psychres.2017.05.036. Epub 2017 May 22.

PMID:
28550757
8.

DNA methylation directly downregulates human cathelicidin antimicrobial peptide gene (CAMP) promoter activity.

Chen X, Qi G, Qin M, Zou Y, Zhong K, Tang Y, Guo Y, Jiang X, Liang L, Zou X.

Oncotarget. 2017 Apr 25;8(17):27943-27952. doi: 10.18632/oncotarget.15847.

9.

Circulating cathelicidin LL-37 in adult patients with pulmonary infectious diseases.

Majewski K, Żelechowska P, Brzezińska-Błaszczyk E.

Clin Invest Med. 2017 Feb 19;40(1):E34-E39.

PMID:
28218580
10.

Antimicrobial peptide LL-37 participates in the transcriptional regulation of melanoma cells.

Muñoz M, Craske M, Severino P, de Lima TM, Labhart P, Chammas R, Velasco IT, Machado MC, Egan B, Nakaya HI, Pinheiro da Silva F.

J Cancer. 2016 Nov 26;7(15):2341-2345. eCollection 2016.

11.

Molecular mechanisms of LL-37-induced receptor activation: An overview.

Verjans ET, Zels S, Luyten W, Landuyt B, Schoofs L.

Peptides. 2016 Nov;85:16-26. doi: 10.1016/j.peptides.2016.09.002. Epub 2016 Sep 5. Review.

PMID:
27609777
12.

The Association between Serum 25-Hydroxy Vitamin D Level and Urine Cathelicidin in Children with a Urinary Tract Infection.

Övünç Hacıhamdioğlu D, Altun D, Hacıhamdioğlu B, Çekmez F, Aydemir G, Kul M, Müftüoğlu T, Süleymanoğlu S, Karademir F.

J Clin Res Pediatr Endocrinol. 2016 Sep 1;8(3):325-9. doi: 10.4274/jcrpe.2563. Epub 2016 May 16.

13.

Carbamylated LL-37 as a modulator of the immune response.

Koro C, Hellvard A, Delaleu N, Binder V, Scavenius C, Bergum B, Główczyk I, Roberts HM, Chapple IL, Grant MM, Rapala-Kozik M, Klaga K, Enghild JJ, Potempa J, Mydel P.

Innate Immun. 2016 Apr;22(3):218-29. doi: 10.1177/1753425916631404. Epub 2016 Feb 15.

14.

Beyond anti-microbial properties: The role of cathelicidin in allergic rhinitis.

Dilek F, Gultepe B, Ozkaya E, Yazici M, Gedik AH, Cakir E.

Allergol Immunopathol (Madr). 2016 Jul-Aug;44(4):297-302. doi: 10.1016/j.aller.2015.07.006. Epub 2016 Jan 8.

PMID:
26777417
15.

Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37.

Schögler A, Muster RJ, Kieninger E, Casaulta C, Tapparel C, Jung A, Moeller A, Geiser T, Regamey N, Alves MP.

Eur Respir J. 2016 Feb;47(2):520-30. doi: 10.1183/13993003.00665-2015. Epub 2015 Nov 19.

16.

The human cathelicidin LL-37--A pore-forming antibacterial peptide and host-cell modulator.

Xhindoli D, Pacor S, Benincasa M, Scocchi M, Gennaro R, Tossi A.

Biochim Biophys Acta. 2016 Mar;1858(3):546-66. doi: 10.1016/j.bbamem.2015.11.003. Epub 2015 Nov 10. Review.

17.

A Spectroscopic Study of the Aggregation State of the Human Antimicrobial Peptide LL-37 in Bacterial versus Host Cell Model Membranes.

Bonucci A, Caldaroni E, Balducci E, Pogni R.

Biochemistry. 2015 Nov 17;54(45):6760-8. doi: 10.1021/acs.biochem.5b00813. Epub 2015 Nov 4.

PMID:
26502164
18.

Vitamin D3 modulates the innate immune response through regulation of the hCAP-18/LL-37 gene expression and cytokine production.

Svensson D, Nebel D, Nilsson BO.

Inflamm Res. 2016 Jan;65(1):25-32. doi: 10.1007/s00011-015-0884-z. Epub 2015 Oct 3. Review.

PMID:
26433491
19.

Cathelicidin as a link between sarcoidosis and tuberculosis.

Korucu E, Pur Ozyigit L, Ortakoylu MG, Bahadir A, Akalin ES, Kara A, Uzun H, Onal B, Caglar E.

Sarcoidosis Vasc Diffuse Lung Dis. 2015 Sep 14;32(3):222-7.

PMID:
26422567
20.

LL-37 immunomodulatory activity during Mycobacterium tuberculosis infection in macrophages.

Torres-Juarez F, Cardenas-Vargas A, Montoya-Rosales A, González-Curiel I, Garcia-Hernandez MH, Enciso-Moreno JA, Hancock RE, Rivas-Santiago B.

Infect Immun. 2015 Dec;83(12):4495-503. doi: 10.1128/IAI.00936-15. Epub 2015 Sep 8.

Supplemental Content

Support Center